The companies will work together on cardiac safety studies in Japan
Rochester, N.Y. and Tokyo, Japan - iCardiac Technologies, Inc., a market and innovation leader in cardiac safety and respiratory studies, and SNBL CPC Japan, an experienced and reputable Site Management Organization (SMO) in Japan, have announced that they will collaborate on cardiac safety studies in Japan. The collaboration will involve both Thorough QT (TQT) studies as well as QT assessment in Phase I studies. It will also enable CPC Clinical Trial Hospital of Medipolis Medical Research Institute, a highly experienced Phase I site, which SNBL CPC Japan has been supporting, to offer iCardiac’s advanced High Precision QT and Early Precision QT analysis methodologies to its sponsors. The companies will partner to further educate the Japanese pharmaceutical market on scientific and regulatory changes enabling QT assessment as part of Phase I studies. The agreement stems from recent developments involving iCardiac’s central role in conducting a validation study demonstrating the reliability of using QT data obtained from Phase I studies. This approach of using Phase I data for regulatory decision-making, which enables an alternative path to conducting a TQT study, was approved in December 2015 by the International Council for Harmonisation. Since then, Japanese regulators have approved a TQT waiver for an iCardiac customer. “We are honored to be working with SNBL group, a preeminent provider of clinical trials services. iCardiac has been at the forefront of developing, validating, and popularizing the use of early QT data as an alternative to doing a TQT study, and we are extremely pleased to have a partner to offer these advanced services in the Japanese market,” said Alex Zapesochny, President & CEO of iCardiac Technologies. Hisao Nakajima, President of SNBL CPC Japan, echoed, “We are also honored to introduce into Japan the advanced QT assessments developed by iCardiac. SNBL group is very pleased to serve our clients, pharmaceutical companies, for efficient drug development through the new cardiac safety technologies stemming from this collaboration.”
About iCardiac Technologies
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for cardiac safety and respiratory services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit:
www.icardiac.com
.
About SNBL Clinical Pharmacology Center, Ltd. and Shin Nippon Biomedical Laboratories Ltd
SNBL Clinical Pharmacology Center, Ltd. (SNBL CPC Japan) has provided site management services for clinical trials, as site management organization (SMO) in Japan for over 15 years. It is a wholly owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), a listed public company on Tokyo Stock Exchange. For more than 55 years, SNBL has been a leader in helping biopharmaceutical companies generate high-quality data with the exceptional precision needed to rapidly advance new medical therapies and innovations that improve patients’ lives. Today, SNBL has operations in Japan, the United States, China, and Cambodia, with headquarters in Tokyo, Japan. For more information, please visit:
http://www.snbl.co.jp/
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.